If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
CGRP monoclonal antibodies are indicated for the preventive treatment of migraine in adults.3-6
During the lasmiditan phase 3 studies in adult patients for the acute treatment of migraine
Concomitant use of lasmiditan with CGRP monoclonal antibodies has not been studied.
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222-e2232. http://dx.doi.org/10.1212/WNL.0000000000006641
2Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894-1904. http://dx.doi.org/10.1093/brain/awz134
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
4Aimovig [package insert]. Thousand Oaks, CA: Novartis; 2019.
5Ajovy [package insert]. North Wales, PA: Teva; 2018.
6Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
CGRP = calcitonin gene-related peptide
Date of Last Review: August 27, 2018